Lung Stereotactic Body Radiation Therapy in a Patient with Severe Lung Function Impairment Allowed by Gallium-68 Perfusion PET/CT Imaging: A Case Report.
Gallium-68 perfusion lung PET/CT
case report
radiation-induced lung injury
stereotactic radiotherapy
very severe chronic obstructive pulmonary disease
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
14 Feb 2023
14 Feb 2023
Historique:
received:
01
02
2023
revised:
09
02
2023
accepted:
13
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Lung stereotactic body radiotherapy (SBRT) is increasingly proposed, especially for patients with poor lung function who are not eligible for surgery. However, radiation-induced lung injury remains a significant treatment-related adverse event in these patients. Moreover, for patients with very severe COPD, we have very few data about the safety of SBRT for lung cancer. We present the case of a female with very severe chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in one second (FEV1) of 0.23 L (11%), for whom a localized lung tumor was found. Lung SBRT was the only possible treatment. It was allowed and safely performed, based on a pre-therapeutic evaluation of regional lung function with Gallium-68 perfusion lung positron emission tomography combined with computed tomography (PET/CT). This is the first case report to highlight the potential use of a Gallium-68 perfusion PET/CT in order to safely select patients with very severe COPD who can benefit from SBRT.
Identifiants
pubmed: 36832204
pii: diagnostics13040718
doi: 10.3390/diagnostics13040718
pmc: PMC9955343
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Radiat Res. 2020 Nov 16;61(6):903-907
pubmed: 32880653
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):989-96
pubmed: 26581137
Technol Cancer Res Treat. 2016 Feb;15(1):114-21
pubmed: 25575575
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Br J Radiol. 2016 Dec;89(1068):20160560
pubmed: 27805837
Radiother Oncol. 2021 Mar;156:153-159
pubmed: 33333139
Semin Nucl Med. 2019 Jan;49(1):71-81
pubmed: 30545520
Pharmaceuticals (Basel). 2022 Apr 22;15(5):
pubmed: 35631345
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56
pubmed: 21640513
Jpn J Clin Oncol. 2017 Jan 9;47(3):277-281
pubmed: 28073946
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e545-9
pubmed: 22436782
EJNMMI Res. 2017 Oct 10;7(1):82
pubmed: 29019109
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62
pubmed: 21035956
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Radiat Oncol. 2020 Feb 27;15(1):61
pubmed: 32106868
Radiother Oncol. 2013 Oct;109(1):95-9
pubmed: 24183862
Nat Rev Clin Oncol. 2012 Dec;9(12):712-20
pubmed: 23149896